LAUSR

T the long waiting times for solid organ transplants, high rates of discard of organs from deceased donors with hepatitis C virus (HCV), and advent of directacting antiviral (DAA) agents have created a dialogue about the use of organs from HCV-positive donors for HCVnegative recipients. In this issue, Trotter et al examined this topic in 3 parts: first, how many potential donors in the United Kingdom are ruled out due to HCV-positive or injection drug use status? Second, what were the trends in utilization versus discard of recovered HCV-positive deceased donor organs in the United Kingdom? And third, what is the cost-effectiveness of transplanting kidneys from HCVpositive deceased donors into HCV-negative recipients? To quantify the potential increase in transplants if HCVpositive donors were not ruled out because of the HCV status, Trotter et al studied the UK Potential Donor Audit, a registry of all individuals younger than 80 years who die in critical care units in the United Kingdom. They found that 120 individuals in the Potential Donor Audit between 2009 and 2016 were not considered as potential donors solely due to injection drug use orHCV-positive status. A limitation in this step was the lack of laboratory testing to identifyHCV antibodyversusRNAstatus of potential donors. Trotter et al then examined 244 HCV-positive deceased donors in the UK Transplant Registry between 2000 and 2015, of whom only 31% proceeded to donation. The quality of declined organs did not differ from the quality of transplanted organs, and